Keyword: Bristol-Myers Squibb
A CD40-activating antibody combined with BMS's Opdivo and chemo shrunk tumors in 20 out of 24 patients with pancreatic cancer.
Bristol-Myers Squibb has tapped Concerto HealthAI for a multiyear, real-world data project covering a range of different cancers.
The resubmission comes one year after Celgene was rocked by a refusal-to-file notice from the FDA.
The submission comes a year after Celgene received an embarrassing refuse-to-file letter for ozanimod from the FDA.
Bristol-Myers Squibb is picking up Celgene's late-stage JAK inhibitor fedratinib in its $74 billion megamerger with the biotech.
CytomX's R&D update includes the news that partner Bristol-Myers Squibb has dropped three programs, putting pressure on the biotech's share price.
Compugen is “streamlining” its R&D operations to pare down costs and ensure it can afford the phase 1 study of its lead asset, an anti-PVRIG antibody.
Bristol-Myers is testing its leukemia therapy Sprycel in a phase 2 combo study with the anti-PD-1 drug Opdivo in non-small cell lung cancer patients.
Nektar has had a mixed few months as data fed through for its lead cancer drug NKTR-214, but new data in bladder cancer should help longer term
IFM Therapeutics is unveiling its second subsidiary, IFM Due, which will target the cGAS/STING pathway to treat inflammatory and autoimmune disease.